Central Nervous System Paracoccidioidomycosis in an AIDS Patient: Case Report

Silva‐Vergara, Mario León; Rocha, Ivonete Helena; Vasconcelos, Rakel Rocha; Maltos, André Luiz; Neves, Fernando de Freitas; Teixeira, Luciana de Almeida Silva; Mora, Delio José

doi:10.1007/s11046-014-9729-5

Cited by 17 publications

(27 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the present study, NPCM was more common in the HIV‐infected group compared with the non‐HIV‐infected group; this is in accordance with previous reports. The estimated frequency of NPCM in the HIV/PCM population was 2.5%; to the present date, only five cases have been described; CD4 cell counts were between 25 and 193 cells/mm³ [24,25,28] .…”

Section: Discussionsupporting

confidence: 92%

Autopsy and biopsy study of paracoccidioidomycosis and neuroparacoccidioidomycosis with and without HIV co‐infection

Almeida

Roza

Salvador

et al. 2018

Mycoses

View full text Add to dashboard Cite

Paracoccidioidomycosis (PCM) is a systemic mycosis prevalent among immunocompetent patients in Latin America. This study aimed to describe the frequency, demographics and clinical characteristics of central nervous system PCM (NPCM) and PCM in an endemic region, and the impact of human immunosuppression virus (HIV) co-infection. This was a retrospective study of autopsy and biopsy reports from the Medical Pathology Section of the Hospital de Clinicas, UFPR, Curitiba, Southern Brazil, between 1951 and 2014. PCM was present in 0.1% of 378,323 cases examined, with 5.7% being NPCM. Infection was prevalent in working-age men, agricultural workers and rural residents. Numbers of HIV autopsy cases increased over time, while those of PCM cases decreased. Prevalence of co-infection of HIV/PCM and HIV/NPCM was 1.6%, and 0.4%, respectively. Adrenals were affected more frequently in the NPCM group compared with the PCM group. Mortality was higher on NPCM group. The clinical course of PCM in HIV patients resembles an acute/sub-acute infection. Association of NPCM and HIV is rare, while diagnosis of NPCM is difficult, it should be considered a differential diagnosis in HIV patients who live in, or have visited, endemic areas and present with neurological symptoms.

show abstract

Section: Discussionsupporting

confidence: 92%

Autopsy and biopsy study of paracoccidioidomycosis and neuroparacoccidioidomycosis with and without HIV co‐infection

Almeida

Roza

Salvador

et al. 2018

Mycoses

View full text Add to dashboard Cite

show abstract

“…The 18 reports left provided 44 cases. 1,4,16,17,23,[25][26][27][28][29][30][31][32][33][34][35][36][37] The information available were categorized and the results are in ►Table 1.…”

Section: Discussionmentioning

confidence: 99%

Neuroparacoccidioidomycosis: Case Report and Literature Review

Morais¹,

Georgeto

Haddad

et al. 2018

Arq Bras Neurocir

View full text Add to dashboard Cite

Introduction Paracoccidioidomycosis (PCM) is a systemic mycosis caused by the fungus Paracoccidioides brasiliensis, and it can compromise the central nervous system (CNS) in 10-27% of all cases. Case Report A 31-year-old man presented to the Emergency Department with headache, left-sided weakness, clonus at the ankle and a positive Babinski sign. Head computed tomography (CT) and magnetic resonance imaging (MRI) scans showed a 5.1 Â 3.8 cm lobulated lesion with areas of liquefaction in the right centrum semiovale. Discussion Central nervous system PCM can mimic a brain tumor, and most cases are diagnosed by biopsy of the lesion. The treatment includes antibiotics, but some cases require surgery. Conclusion Due to high morbimortality rates, the diagnosis must be considered, and early treatment started in patients who live in rural regions endemic for PCM when a ring-enhancing mass associated with perilesional edema is observed on MRI scans.

show abstract

“…It can be used, exceptionally, in severe forms of PCM, in doses similar to those used in other invasive infections. [15][16][17][18][19][20][21][22][23] ■ amphotericin: it has several pharmacological presentations and only IV use. Amphotericin B (amphotericin B deoxycholate) is presented in bottles with 50 mg for IV use after dilution in SGI, in slow infusion, for three to five hours or more, in concentrations of not more than 10 mg/mL.…”

Section: Treatmentmentioning

confidence: 99%

Paracoccidioidomycosis (Lutz-Splendore-Almeida disease): treatment, duration of treatment, recurrence, paradoxical reaction, prognosis, prophylaxis

Vasconcellos¹,

Ambrósio

Camelo

et al. 2014

Revista Médica De Minas Gerais

View full text Add to dashboard Cite

Paracoccidioidomycosis, despite being the most important deep mycosis in Latin America, still has many blindspots in terms of its approach, especially in relation to duration of treatment, cure control and prophylaxis. Depending on severity, the following can be used in the treatment: sulfonamides, azoles (itraconazole and ketoconazole), and amphotericin. The prognosis depends on severity, time between onset and diagnosis, and therapy instituted. In mild forms, prognosis is good; in moderate and severe forms, for which there is risk of developing sequelae and death, it is guarded.

show abstract

Central Nervous System Paracoccidioidomycosis in an AIDS Patient: Case Report

Cited by 17 publications

References 24 publications

Autopsy and biopsy study of paracoccidioidomycosis and neuroparacoccidioidomycosis with and without HIV co‐infection

Autopsy and biopsy study of paracoccidioidomycosis and neuroparacoccidioidomycosis with and without HIV co‐infection

Neuroparacoccidioidomycosis: Case Report and Literature Review

Paracoccidioidomycosis (Lutz-Splendore-Almeida disease): treatment, duration of treatment, recurrence, paradoxical reaction, prognosis, prophylaxis

Contact Info

Product

Resources

About